Resitu Strengthens C-Suite With New CEO as it Prepares for Commercialization of its Breast Tumor Removal Device
- The company is developing pioneering devices for the total excision of breast tumors
- Resitu’s new CEO, Åsa Runnäs, brings two decades of experience in successfully commercializing medical devices
- Resitu’s devices aims to mitigate the need for open surgery, with the goal of lowering the healthcare burden of patients with suspected cancer
Uppsala, Sweden, April 25, 2025. Resitu, a Swedish company developing pioneering devices for full excision of breast tumors, has appointed Åsa Runnäs as the company’s CEO, building on her 20 years of experience in device regulation and commercialization.
Åsa Runnäs is one of Resitu’s core investors, part of its founding team, and has served as the company’s chief strategy officer. Prior to Resitu, she was CEO of several medtech consultancy firms.
The news comes as Resitu prepares for the launch of its first device, a vacuum-assisted, minimally invasive, handheld instrument for the excision of breast lesions for diagnostic analysis.
Resitu recently demonstrated its device to 40 leading breast surgeons at the Uppsala Breast Meeting, held at Uppsala University in Sweden. During guided workshops, the surgeons experienced hands-on use of Resitu’s devices.
“We are very encouraged by the feedback from surgeons at the workshop. It reinforces our view that the Resitu devices will play an important role in breast tumor management,” commented Åsa Runnäs. “The feedback also confirms that Resitu’s devices are easy to use, applicable to a wide patient population, and an important response to an unmet global need.”
Demand will be high. The instrument is developed by renowned surgeons, and the company’s absolute focus is to ensure that healthcare systems around the world will be able to access the device as soon as possible.
“By radically rethinking breast tumor management, we will be able to offer healthcare providers a much-needed excision-led, minimal invasive approach for large tissue removal. This solution will not only ease the strain on healthcare systems but, most importantly, it will shorten the stressful time patients experience during the diagnostic process. This is the way forward for 21st Century care,” added Runnäs.
Contact
For more information, or to speak to one of Resitu’s team or a surgeon who has used Resitu’s device, please contact:
Barnaby Pickering, Director, RHA Communications. Barnaby@rhacomms.eu
Alexandra Hoegberg, Director, RHA Communications. Alexandra@rhacomms.eu
About Resitu
Resitu Medical is a Swedish company that develops instruments for the safe removal of whole breast lesions without open surgery, potentially revolutionizing how breast cancer is managed. The company was founded in 2019 by Dr Per Hedén who, in his plastic surgical practice, needed to remove large intact tissue samples. He realized that beyond plastics, the system could be used to remove large tissue samples – or whole tumors.
Resitu has progressed through early development stages, and is about to launch of its first device. The company aims to offer the device at multiple ‘bore’ sizes – 9mm, 12mm, 14mm, 16mm and 18mm.
Resitu is first targeting the European and US market, where it already has the backing of key clinicians throughout the Nordics, UK, Germany, Switzerland and US. From there, it will launch in the Middle East and selected African countries. With this expansion, Resitu plans to make its system available in currently underserved markets, where a minimally invasive, lower-burden approach naturally offers advantages over open surgery. Read more: www.resitu.com/
About Breast Cancer
Breast cancer is the world’s most prevalent form of cancer. In 2022, approximately 2.3 million cases were diagnosed worldwide, with 670,000 people dying of the disease. Half of all cases are linked only to age and gender, and have no predictive, or underlying causes.
In terms of healthcare burden, the impact of breast cancer is felt differently on a geographical basis. In countries with a high Human Development Index, 1 in 12 women are diagnosed with breast cancer during their lifetime, yet only 1 in 71 women die of it thanks to advances in treatments including effective open surgery, advanced chemotherapeutic agents, and radiotherapy.
Meanwhile, in poorer countries with a low HDI, 1 in 27 women are diagnosed with breast cancer during their lifetime, with 1 out of 48 women dying from it. In many countries, there are no available treatments.
